LETTER TO EDITOR
Year : 2016 | Volume
: 8 | Issue : 3 | Page : 169--170
Patent foramen ovale and migraine: Casual or causal
Adrija Hajra1, Dhrubajyoti Bandyopadhyay2,
1 Department of Internal Medicine, Institute of Post-Graduate Medical Education and Research (IPGMER), Kolkata, West Bengal, India
2 Department of Accident and Emergency, Lady Hardinge Medical College, New Delhi, India
Department of Internal Medicine, Institute of Post-Graduate Medical Education and Research (IPGMER), Kolkata, West Bengal
|How to cite this article:|
Hajra A, Bandyopadhyay D. Patent foramen ovale and migraine: Casual or causal.North Am J Med Sci 2016;8:169-170
|How to cite this URL:|
Hajra A, Bandyopadhyay D. Patent foramen ovale and migraine: Casual or causal. North Am J Med Sci [serial online] 2016 [cited 2020 Nov 30 ];8:169-170
Available from: https://www.najms.org/text.asp?2016/8/3/169/179139
The atrial septum primum and septum secundum are usually closed by the first year of age. Incomplete closure of the septum primum and septum secundum results in patent foramen ovale (PFO). On the other hand, migraine is a common condition characterized by unilateral headache associated with nausea, photophobia, and phonophobia. These two conditions may be related to each other.
Various mechanisms have been described to explain this relation. Subclinical emboli, as well as metabolites from the venous circulation bypass the pulmonary circulation through the PFO. They enter the systemic circulation and result in irritation of the trigeminal nerve and brain vasculature. This may trigger a migraine.
A small double-blind crossover study has demonstrated that aspirin, an antiplatelet drug may reduce the formation of platelet-fibrin complexes and improve a migraine. It may be possible that increased platelet activation may be a risk factor for a migraine through the action of serotonin. Transient hypoxemia resulting from shunting of blood through the PFO causes microinfarcts in the brain. It may lead to a migraine. PFO may predispose to subclinical ischemia and paradoxical embolism that may result in triggering the migraine.  Another study has postulated the eustachian valve, Chiari's network, and migraine with aura can be adjunctive risk factors for paradoxical embolism in the evaluation of both symptomatic and asymptomatic PFO patients.  It has been demonstrated that PFO is not just an example of migraine comorbidity but exerts a causal effect in the triggering of the aura by applying the criteria proposed by Bradford Hill. 
Epidemiologic data have shown that PFO and migraine are related. Two Italian groups were the first to report, in case-control studies, a significantly higher prevalence of PFO in subjects with a migraine with aura. They have used transcranial Doppler ultrasonography (TCD) for evaluation of patients. A study of young cryptogenic stroke patients has shown increased prevalence of a migraine in patients with PFO. A retrospective study showed that migraine patients with PFO have higher right-to-left shunting compared to controls. In a meta-analysis of seven studies, it was concluded that there was only low-grade evidence supporting the association between PFO and migraine.  A study published on 2012 demonstrated that the intravenous injection of air bubbles results in bioelectrical disturbances in the brain of patients with a migraine with aura. They have large right-to-left cardiac shunts. On the contrary, this effect was absent in patients with equally large right-to-left cardiac shunts, but without a migraine. However, the majority of these patients did not experience a headache. It suggested that subclinical hypoxia-ischemia induced by paradoxical cerebral embolism was not a common cause of migraine attacks in a migraine with aura patients with large PFOs. But they may occasionally trigger aura and headache in susceptible patients, especially if the clearance of the embolus is delayed. 
It is quite natural that after all these studies, there was a search for the fact about whether closure of PFO can reduce migraine or not. Migraine intervention with STARFlex technology (MIST) trial is the only completed randomized double-blind sham-controlled study. It showed reduced median total migraine headache days in the PFO closure group compared to the control group.  Studies have demonstrated that primary transcatheter closure of the PFO resulted in a significant reduction in migraine.  In Percutaneous Closure of PFO in Migraine with Aura (PRIMA) trial, out of 107 participants, 53 patients were put on Amplatzer device for PFO closure. A total number of 54 patients were placed on medical therapy. There was no significant difference in migraine days per month in these two groups. But patients with PFO closure showed significant (P < 0.01) reduction in migraine with aura attacks. 
There were some studies started on the relationship between PFO and migraine as well as on the effect of PFO closure on migraine.  But more data are required for the conclusion. It is still unclear if there is a causal relationship or simply a coexistence of these two conditions. We hope that future research works will enlighten our knowledge about this topic.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
|1||Sathasivam S, Sathasivam S. Patent foramen ovale and migraine: What is the relationship between the two? J Cardiol 2013;61:256-9.|
|2||Rigatelli G, Dell'avvocata F, Cardaioli P, Giordan M, Braggion G, Aggio S, et al. Migraine-patent foramen ovale connection: Role of prominent eustachian valve and large Chiari network in migrainous patients. Am J Med Sci 2008;336:458-61.|
|3||Anzola GP, Mazzucco S. The patent foramen ovale-migraine connection: A new perspective to demonstrate a causal relation. Neurol Sci 2008;29(Suppl 1):S15-8.|
|4||Sevgi EB, Erdener SE, Demirci M, Topcuoglu MA, Dalkara T. Paradoxical air microembolism induces cerebral bioelectrical abnormalities and occasionally headache in patent foramen ovale patients with migraine. J Am Heart Assoc 2012;1:e001735.|
|5||Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Wells C, et al. Migraine intervention with STARFlex Technology (MIST) trial: A prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 2008;117:1397-404.|
|6||Rigatelli G, Cardaioli P, Giordan M, Dell'Avvocata F, Braggion G, Chianaglia M, et al. Transcatheter interatrial shunt closure as a cure for migraine: Can it be justified by paradoxical embolism-risk-driven criteria? Am J Med Sci 2009;337:179-81.|
|7||Hildick-Smith D. Percutaneous closure of patent foramen ovale in migraine with aura (PRIMA). Presented at Transcatheter Cardiovascular Therapeutics. Washington DC, United States; 2014. |
|8||Tarantini G, D'Amico G, Bettella N, Mojoli M, Rigatelli G. Patent foramen ovale closure and migraine time course: Clues for positive interaction. Int J Cardiol 2015;195:235-6.|